The clinical phenotype of primary and post–polycythemia vera and postessential
thrombocythemia myelofibrosis (MF) is dominated by splenomegaly, symptomatology, a …

New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Despite the approval of Janus kinase inhibitors and novel agents for patients with
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …

To develop a prognostic model for patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients …

We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation
(HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant …

Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative
treatment for myelofibrosis (MF). Relapse occurs in 10–30% and remains a major factor for …

Splenomegaly is a hallmark of myelofibrosis (MF), and reports on the impact of spleen size
on the outcome of allo-HSCT have been conflicting, possibly due to differences in methods …

Close HLA matching of donors and recipients has been the dogma for successful allogeneic
blood or marrow transplantation (alloBMT), to limit the complications of graft-versus-host …

We describe outcomes after post-transplantation cyclophosphamide and nonmyeloablative
conditioning-based allogeneic blood or marrow transplantation for myelofibrosis using …